Parabilis Medicines, Inc. (PBLS) company profile
PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$28.25−0.20 (-0.70%)
Close on Nov 17, 2026Market cap $3.49BP/E –Yield –
About Parabilis Medicines
Pharmaceutical Preparations, SIC 2834
Parabilis Medicines, Inc. is listed on Nasdaq under the ticker PBLS, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Parabilis Medicines, Inc.
- Headquarters
- Cambridge, MA
- Address
- 30 Acorn Park Drive, 6th Floor 02140
- Phone
- (617) 945-9510
- Website
- parabilismed.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- PBLS
- Exchange
- Nasdaq
- IPO date
- Jun 10, 2026
- Shares outstanding
- 124M, Aug 10, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1657677
- CUSIP
- 698955101
- ISIN
- US6989551014
- FIGI
- BBG00KXR8FS7
- Share class FIGI
- BBG00KXR8FT6
- EIN
- 47-4505725
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mathai Mammen | President & CEO, Director | – |
| Teresa Jurgensen | General Counsel | – |
| Helen Huei-in Ho | See Remarks | – |
| Mohammed Fawzi Benzaghou | Chief Medical Officer | – |
| Rohin Mhatre | See Remarks | – |
| Thomas Rodolpho Kotarakos | Chief Financial Officer | – |
| Craig Tendler | Director | – |
| Capital Healthcare Fund LP RA | Director | – |
| Rajeev M. Shah | Director | – |
| RA Capital Nexus Fund III, L.P. | Director | 6,556,740 |
| Peter Kolchinsky | Director | – |
| Ra Capital Management, L.P. | Director | 26,529,686 |
| Alan Sebulsky | Director | 25,935 |
| Edward M. Fitzgerald | Director | 14,688 |
| Alexis Borisy | Director | 105,414 |
| Richard Klausner | Director | – |
| Barbara Weber | Director | – |
| Jake Simson | Director | – |
| Krishna Yeshwant | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 10, 2026
- Offer price
- $20.00
- Securities offered
- 33,500,000
- Gross proceeds
- $670.00M
- Exchange
- Nasdaq
- First trading day
- Jun 10, 2026
- First-day close
- $31.60+58.0%
- Lock-up ends (est.)
- Dec 7, 2026
“The initial public offering price per share is $20.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 10, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 5, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 2, 2022 | Name change | Name changed from FOG PHARMACEUTICALS, INC. to Parabilis Medicines, Inc. |
See a number that looks wrong?